HEALTH
- Share via
Roche to Sell Syntex’s Medical Diagnostic Unit: The company said it will sell the business under an agreement with the Federal Trade Commission, clearing the way for a $5.3-billion merger of the two companies. Roche Holding Ltd.’s $24-a-share tender offer for Syntex Corp. has been extended several times since being announced May 2 and will now expire Wednesday. Syntex’s Syva Co. is a major provider of tests that detect illegal drugs. Roche Diagnostics, based in Switzerland, is also a leading provider, prompting the FTC’s concerns. Under the agreement, Syva must be sold within a year of the merger.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.